

Tyrian Diagnostics Limited ACN 080 277 998

NEW CROP QUALITY TEST FOR BAYER CROPSCIENCE MOVES STEP CLOSER TO MARKET

SYDNEY, AUSTRALIA 24 NOVEMBER 2009: Tyrian Diagnostics Limited (ASX:TDX) announced today that it had moved a step closer to launching its second agricultural diagnostic test as part of its collaboration with Bayer CropScience. The new test, to which Bayer CropScience has obtained the exclusive worldwide license from Tyrian, is designed to assess crops for contaminants that affect grain pricing.

Tyrian has just completed the manufacture of several thousand prototype tests for a multi-site evaluation of the second test. Bayer gave the green light for this next stage of product development following the recent successful completion of a proof of concept study in which several hundred prototype tests were evaluated for product feasibility. Laboratory-based testing will be performed using the prototype tests in a multi-site evaluation across North America and Europe.

In this programme, Tyrian is using its DiagnostIQ™ platform and relevant antibody to develop a rapid, quantitative, Point of Need test. Initial product evaluation showed early promise that Tyrian's test was rapid, simple to use, reproducible and gave results that performed well when compared with the current laboratory-based standard method (HPLC) – a method that requires specially skilled operators.

“Adding to our pipeline of DiagnostIQ products through our ongoing partnership with Bayer CropScience continues the validation of our proprietary diagnostic test platform,” said Jenny Harry, PhD, Chief Executive Officer of Tyrian. “We are delighted to be developing new products in an area where there is significant market demand, no requirement for regulatory approvals, and with a commercialisation partner with exceptional market reach.”

This second product forms part of Bayer CropScience's product portfolio being developed around Tyrian's DiagnostIQ test device and reader (ReadRite® Immunoscanner – a reader developed by Tyrian for quantitative measurement). The first product in the portfolio is the ReadRite Alpha Amylase - a test for rain damage in wheat currently marketed in Canada.

About DiagnostIQ

DiagnostIQ is a patented diagnostic test platform suitable for the development of antibody-based, Point-of-Need diagnostic tests. The platform is simple to use, rapid, robust, sensitive and suitable for analysing complex samples. A combination of features provides a versatile platform for use with a variety of sample types and products for medical, veterinary and agricultural applications. The DiagnostIQ test can provide a visual result and/or be used with a portable digital reader when quantitative test results are required. Bayer CropScience has obtained the exclusive worldwide license for two application areas for the DiagnostIQ platform.

About DiagnostIQ Reader

The DiagnostIQ Reader is a proprietary device that utilizes optical detection technology combined with customized software to provide a quantitative measure of the level of diagnostic targets in samples processed in Tyrian's point of need DiagnostIQ tests. The

Reader can be configured to detect diagnostic targets in a wide range of sample types, and therefore has utility in the healthcare, agricultural, and veterinary fields. Tyrian supplies Bayer CropScience with the DiagnostIQ Reader for sale under Bayer CropScience's ReadRite logo for use with its portfolio of agricultural products.

About Tyrian Diagnostics

Tyrian Diagnostics (ASX: TDX) is an Australian-based company that develops and commercialises rapid point-of-need diagnostics.

The Company has an innovative and proprietary diagnostic test platform, DiagnostIQ, and Tyrian's strategy is to deliver near term revenues through partnering this technology for the development and commercialisation of clinical and non-clinical diagnostic tests. The first product is a point-of-need diagnostic for measuring wheat quality, ReadRite Alpha Amylase, developed in partnership with Bayer CropScience AG, with further products under development.

Tyrian also has expertise in discovering and developing biomarkers of disease as targets for diagnostic tests. Tyrian's primary internal programme is the development of its patented biomarkers for molecular and protein-based diagnostic tests for active tuberculosis (TB) and the company is seeking partners for final development and marketing of these tests. Tyrian's longer term plan is to exploit its intellectual property and expertise in respiratory and infectious diseases to achieve higher returns through developing and commercialising proprietary clinical diagnostic products.

Additional information about Tyrian Diagnostics can be found at www.tyriandx.com

Contact:

Tyrian Diagnostics
Lisa Jones
Head of Business & Legal Affairs
+61 2 8877 8947